Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

NCT02086942 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib
DRUG: cyclophosphamide
DRUG: Dexamethasone

Sponsor

Yongping Zhai